

		2016				(HbA1c 6.5%)			
1000		(6.0% HbA1c 6.5%)				1000			
(		)				(			
60	69	20.0%	70	27.0%	60	69	9.8%	70	15.8%
		(				)			
						(			
						QOL			
						)			
						1990			
						HbA1c			
		2008							
		DPP-4		GLP-1		SGLT-2			
		SGLT2		GLP-1					
		2022		9		2			
		2023		10		(		66 10 715-33 2023) Step1	
(BMI 25kg/m2				)		(BMI<25kg/m2			
)				Step2					
Step3						Additional benefits			
Step4									
		40%		1998				2015	
1		2017		12		(38%)		(20%)	
				(10%)				4	
(eGFR<30ml/min/1.73m2)						4		53	
		4				(38		n=26) (38	
n=27) 2		4						(58.2±25.2	

vs 67.4±10.1 ) (8.46±5.91g/Cre vs 4.16±4.67g/Cre, p=0.02)  
(3.21±0.64g/dl vs 3.80±0.40g/dl, p<0.01)

Steno-2 (Gaede P, et. al. N Engl J Med.  
2008 Feb 7;358(6):580-91) J-DOIT3 (Ueki K, et. al. Lancet Diabetes Endocrinol. 2017  
Dec;5(12):951-964)

34 34 10 3 2  
(2 15 5 3 16 4 4 3 1 )  
HbA1c (6.72±0.64% vs 7.55±1.86%)

MR ACE /ARB SGLT2 GLP-1  
(Naaman SC, et. al. Diabetes Care. 2023 Sep 1;46(9):1574-1586)

2018 2

13 5

500 600 2020 ( GLP-1 )